It has a history of buying up mature brands from other pharma companies, for example paying $300 million for rights to AstraZeneca's migraine therapy Zomig (zolmitriptan) in a similar deal five ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback